The U.S. Omnipod guidance cut is a key negative, suggesting slowing adoption or competitive pressure; monitor Q3 U.S. trends for confirmation. The strong EPS beat and international momentum provide some offset, but the stock may face headwinds until management demonstrates U.S. stabilization.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Aug 5 $132.30entry
- T+1 · 3mo ago +4.75%α +4.91% · $138.58
- T+5 · 3mo ago +9.64%α +9.29% · $145.06
- T+20 · 3mo ago +11.97%α +12.57% · $148.14
- T+60 · 19d ago +15.26%α +15.32% · $152.50
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Insulet reported Q2 2026 revenue of $801.7M (+23.5% YoY) and adjusted EPS of $1.66, beating consensus estimates by 14.3%, but lowered FY 2026 U.S. Omnipod constant currency growth guidance from 20-22% to 17-19%, signaling a meaningful deceleration in the domestic business.
Key Financial Metrics
Key Facts
- Q2 2026 revenue $801.7M vs $649.1M YoY, +23.5% as reported, +22.7% constant currency
- GAAP EPS $1.37 (diluted); adjusted EPS $1.66, beating consensus $1.45 by 14.3%
- U.S. Omnipod revenue $544.1M (+20.1% YoY); International Omnipod $251.8M (+35.5% YoY, +32.9% constant currency)
- FY 2026 U.S. Omnipod constant currency growth guidance cut to 17-19% from prior 20-22%
- Total Omnipod FY constant currency guidance trimmed to 21-23% from 22-24%
- Adjusted operating margin 19.3% (+140 bps YoY); adjusted EPS growth guidance raised to 30% from 25%
- Voluntary medical device correction costs of $21.9M in Q2 related to March and May 2026 actions
Financial Impact
EPS beat $0.21 vs consensus ($1.66 vs $1.45), but FY U.S. growth guidance cut by ~3 percentage points
Risk Factors
- U.S. Omnipod growth deceleration from type 2 diabetes scaling challenges
- Voluntary medical device corrections creating ongoing warranty and reputational costs
- Competitive pressure from Tandem Diabetes Care and Medtronic's automated insulin delivery systems
- Potential further downward revision if Q3 trends disappoint
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001145197-26-000167 |
| Document: podd-20260805.htm | 0001145197-26-000167 |
| Document: 0001145197-26-000167-index-headers.html | 0001145197-26-000167 |
| Document: 0001145197-26-000167-index.html | 0001145197-26-000167 |
| Document: 0001145197-26-000167.txt | 0001145197-26-000167 |
| 8-K Data (Synthetic) | 0001145197-26-000167 |
Track record
11 reports on PODD
2 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +13.05% at T+60 after the Jul 24, 2026 report. 3 of 5 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 4/10 Entry price pending
- Nov 13, 20263d ago SC 13G Neutral 3/10 Entry $152.48 Now $145.29 −4.72% settles Feb 11
- Nov 4, 202612d ago 8-K Bullish 6/10 Entry $165.02 Now $145.29 −11.96% settles Feb 2
- Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $148.93 Now $145.29 −2.44% settles Jan 26
- Oct 23, 202624d ago Institutional Cluster Neutral 3/10 Entry $149.01 Now $145.29 −2.50% settles Jan 21
- Sep 21, 20268w ago 8-K Bullish 6/10 Entry $139.38 Now $145.29 +4.24% settles Dec 16
- Aug 5, 202614w ago 8-K Mixed 5/10 Viewing Entry $132.30 to $152.50 Now $145.29 +9.82% ▲ +15.26% +15.32% vs SPY
- Jul 24, 202616w ago Institutional Cluster Bearish 5/10 Entry $163.26 to $141.96 Now $145.29 +11.01% ▲ +13.05% +16.77% vs SPY
- May 28, 202624w ago Court Ruling Bearish 7/10 Entry $141.98 to $147.92 Now $145.29 −2.33% ▼ −4.18% −2.71% vs SPY
- May 6, 202627w ago 8-K Bullish 7/10 Entry $150.52 to $165.68 Now $145.29 −3.48% ▲ +10.07% +9.00% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers